Aurinia Pharmaceuticals

Yahoo Finance • 23 days ago

Mutiny At Aurinia Pharmaceuticals? Biotech Soars On C-Suite Shake-Up.

Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition. Continue Reading... Full story

Yahoo Finance • 28 days ago

Evommune Stock Sees RS Rating Rise To 91

On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's... Full story

Yahoo Finance • last month

W.R. Berkley, Ziff Davis, and More Stocks See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VI... Full story

Yahoo Finance • 4 months ago

Top SA Quant rated small-cap stocks as Russell 2000 notches a record close

[Financial term Small Capitalization Stocks on gray and red finance background from graphs, charts. Trend Up and Down, Flat. 3D render] Vladimir Zakharov/iStock via Getty Images The Russell 2000 index (RTY [https://seekingalpha.com/symbol... Full story

Yahoo Finance • 5 months ago

Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers George Tidmarsh has lost his job as director of the U.S. FDA's Center for Drug Evaluation and Research amid accusations that he leveled false statements against a Canad... Full story

Yahoo Finance • 6 months ago

Aurinia Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) have crossed above the average analyst 12-month target price of $11.71, changing hands for $11.84/share. When a stock reaches the target an analyst has set, the analy... Full story

Yahoo Finance • 6 months ago

Xencor Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Xencor shows improving technical performance. Will it continue? Continue Reading View Comments... Full story

Yahoo Finance • 6 months ago

Sector Update: Health Care Stocks Climb Late Afternoon

Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index adding 2.5% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 6 months ago

Aurinia responds after top FDA official’s comment on lead drug

[US Food and Drug Administration (FDA)] Aurinia Pharmaceuticals (NASDAQ:AUPH [https://seekingalpha.com/symbol/AUPH]) traded ~7% higher in the premarket on Tuesday after the company responded to a comment made by a top FDA regulator regard... Full story

Yahoo Finance • 7 months ago

Aurinia Pharma Reaffirms LUPKYNIS Safety And Efficacy Following Retracted FDA Official's Post

(RTTNews) - Responding to a now retracted LinkedIn post referencing voclosporin by an FDA official, Aurinia Pharmaceuticals Inc. (AUPH) stated that it stands firmly behind the favorable benefit/risk profile of LUPKYNIS (voclosporin). The d... Full story

Yahoo Finance • 7 months ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • 7 months ago

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH [https://www.chartmill.com/stock/quote/AUPH]) has become an interesting candidate for growth investors using the screening method from Louis Navellier's "The Little Book That Makes You Rich." The pr... Full story

Yahoo Finance • 8 months ago

Notable Thursday Option Activity: GS, DDOG, RTX

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Goldman Sachs Group Inc (Symbol: GS), where a total of 38,837 contracts have traded so far, representing approximately 3.9 million unde... Full story

Yahoo Finance • 8 months ago

KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82

On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before. Is KalVista Pharmaceutic... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Aurinia Pharmaceuticals Q2 2025 sees strong growth and stock surge

Aurinia Pharmaceuticals, a $1.56 billion market cap pharmaceutical company, reported a robust performance for the second quarter of 2025, with earnings per share (EPS) and revenue both surpassing market expectations. The company announced... Full story

Yahoo Finance • 8 months ago

Aurinia Pharmaceuticals stock hits 52-week high at 11.81 USD

Aurinia Pharmaceuticals Inc. (AUPH) stock reached a significant milestone, hitting a 52-week high at 11.81 USD. According to InvestingPro data, the company maintains a "GREAT" financial health score, with robust revenue growth of 25.6% and... Full story

Yahoo Finance • 8 months ago

Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration

Earnings Call Insights: Aurinia Pharmaceuticals (AUPH) Q2 2025 MANAGEMENT VIEW * Peter S. Greenleaf, President and CEO, reported "strong growth in total revenue and net product sales in the 3 and 6 months ended June 30, 2025," attribut... Full story

Yahoo Finance • 9 months ago

H.C. Wainwright assumes coverage on Aurinia Pharmaceuticals stock with Buy rating

Investing.com - H.C. Wainwright has assumed coverage on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy rating and a price target of $17.00, according to a research note released Wednesday. Currently trading at $8.95, the stock appears un... Full story

Yahoo Finance • 9 months ago

Bullish Two Hundred Day Moving Average Cross - AUPH

In trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals Inc shares are currently trading up about... Full story